• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体检测性能评估用于 SARS-CoV-2 大规模筛查和检测。

Group testing performance evaluation for SARS-CoV-2 massive scale screening and testing.

机构信息

Department of Computer Engineering, Erciyes University, Kayseri, 38039, Turkey.

Bioinformatics Division, Genome and Stem Cell Center, Erciyes University, Kayseri, 38039, Turkey.

出版信息

BMC Med Res Methodol. 2020 Jul 2;20(1):176. doi: 10.1186/s12874-020-01048-1.

DOI:10.1186/s12874-020-01048-1
PMID:32615934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7330001/
Abstract

BACKGROUND

The capacity of the current molecular testing convention does not allow high-throughput and community level scans of COVID-19 infections. The diameter in the current paradigm of shallow tracing is unlikely to reach the silent clusters that might be as important as the symptomatic cases in the spread of the disease. Group testing is a feasible and promising approach when the resources are scarce and when a relatively low prevalence regime is observed on the population.

METHODS

We employed group testing with a sparse random pooling scheme and conventional group test decoding algorithms both for exact and inexact recovery.

RESULTS

Our simulations showed that significant reduction in per case test numbers (or expansion in total test numbers preserving the number of actual tests conducted) for very sparse prevalence regimes is available. Currently proposed COVID-19 group testing schemes offer a gain up to 15X-20X scale-up. There is a good probability that the required scale up to achieve massive scale testing might be greater in certain scenarios. We investigated if further improvement is available, especially in sparse prevalence occurrence where outbreaks are needed to be avoided by population scans.

CONCLUSION

Our simulations show that sparse random pooling can provide improved efficiency gains compared to conventional group testing or Reed-Solomon error correcting codes. Therefore, we propose that special designs for different scenarios could be available and it is possible to scale up testing capabilities significantly.

摘要

背景

目前的分子检测方法无法进行高通量和社区级别的 COVID-19 感染扫描。在目前的浅层溯源模式下,其检测范围很窄,难以发现那些可能与有症状病例同等重要的静默感染集群。在资源有限且人群中观察到相对较低的流行率时,组检测是一种可行且有前途的方法。

方法

我们采用了稀疏随机池化方案的组检测,并使用传统的组测试解码算法进行精确和不精确的恢复。

结果

我们的模拟结果表明,在非常稀疏的流行率情况下,每个病例的检测数量(或在保持实际检测数量的情况下扩大总检测数量)可以显著减少。目前提出的 COVID-19 组检测方案可提供高达 15 倍至 20 倍的扩展。在某些情况下,可能需要更大的扩展才能实现大规模检测。我们研究了是否可以进一步提高效率,特别是在需要通过人群扫描来避免疫情爆发的稀疏流行情况下。

结论

我们的模拟结果表明,与传统的组检测或 Reed-Solomon 纠错码相比,稀疏随机池化可以提供更高的效率增益。因此,我们提出可以针对不同场景进行特殊设计,并有可能显著提高检测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/97a55b525233/12874_2020_1048_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/431684e920e2/12874_2020_1048_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/24515293146c/12874_2020_1048_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/e268293890a5/12874_2020_1048_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/e3a17ff32dff/12874_2020_1048_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/0ba71503e1f0/12874_2020_1048_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/97a55b525233/12874_2020_1048_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/431684e920e2/12874_2020_1048_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/24515293146c/12874_2020_1048_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/e268293890a5/12874_2020_1048_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/e3a17ff32dff/12874_2020_1048_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/0ba71503e1f0/12874_2020_1048_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1274/7331189/97a55b525233/12874_2020_1048_Fig6_HTML.jpg

相似文献

1
Group testing performance evaluation for SARS-CoV-2 massive scale screening and testing.群体检测性能评估用于 SARS-CoV-2 大规模筛查和检测。
BMC Med Res Methodol. 2020 Jul 2;20(1):176. doi: 10.1186/s12874-020-01048-1.
2
Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening.多阶段分组检测提高大规模 COVID-19 筛查效率。
J Clin Virol. 2020 Jul;128:104382. doi: 10.1016/j.jcv.2020.104382. Epub 2020 Apr 23.
3
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
4
Pooling for SARS-CoV-2 control in care institutions.在护理机构中对 SARS-CoV-2 进行集中控制。
BMC Infect Dis. 2020 Oct 12;20(1):745. doi: 10.1186/s12879-020-05446-0.
5
Assessment of sample pooling for SARS-CoV-2 molecular testing for screening of asymptomatic persons in Tunisia.评估在突尼斯对无症状人群进行 SARS-CoV-2 分子检测时进行样本混合的效果。
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115125. doi: 10.1016/j.diagmicrobio.2020.115125. Epub 2020 Jul 5.
6
Pooled Testing for Expanding COVID-19 Mass Surveillance.用于扩大新冠病毒大规模监测的混合检测
Disaster Med Public Health Prep. 2020 Jun;14(3):e42-e43. doi: 10.1017/dmp.2020.246. Epub 2020 Jul 14.
7
Comparison of four COVID-19 screening strategies to facilitate early case identification within the homeless shelter population: A structured summary of a study protocol for a randomised controlled trial.比较四种 COVID-19 筛查策略,以在无家可归者收容所人群中尽早发现病例:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Nov 23;21(1):941. doi: 10.1186/s13063-020-04890-2.
8
Cost Effectiveness of Sample Pooling to Test for SARS-CoV-2.样本混合检测严重急性呼吸综合征冠状病毒2的成本效益
J Infect Dev Ctries. 2020 Oct 31;14(10):1136-1137. doi: 10.3855/jidc.13935.
9
Is there value in a two-step diagnostic algorithm to confirm SARS-CoV-2 in South Africa?在南非,两步诊断算法用于确诊严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是否有价值?
S Afr Med J. 2020 Jun 2;110(7):564-565. doi: 10.7196/SAMJ.2020.v110i7.14853.
10
Group Testing for Severe Acute Respiratory Syndrome- Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence.群体检测严重急性呼吸综合征冠状病毒 2 以实现检测的快速扩展和发病率的实时监测。
J Infect Dis. 2020 Aug 17;222(6):903-909. doi: 10.1093/infdis/jiaa378.

引用本文的文献

1
Assessment of the Effective Sensitivity of SARS-CoV-2 Sample Pooling Based on a Large-Scale Screening Experience: Retrospective Analysis.基于大规模筛查经验的 SARS-CoV-2 样本混样有效敏感性评估:回顾性分析。
JMIR Public Health Surveill. 2024 Sep 24;10:e54503. doi: 10.2196/54503.
2
Quantitative composite testing model based on measurement uncertainty and its application for the detection of phthalate esters.基于测量不确定度的定量复合检测模型及其在邻苯二甲酸酯检测中的应用
Front Chem. 2023 Sep 18;11:1191669. doi: 10.3389/fchem.2023.1191669. eCollection 2023.
3
Group testing via hypergraph factorization applied to COVID-19.

本文引用的文献

1
Efficient high-throughput SARS-CoV-2 testing to detect asymptomatic carriers.高效高通量 SARS-CoV-2 检测以发现无症状感染者。
Sci Adv. 2020 Sep 11;6(37). doi: 10.1126/sciadv.abc5961. Print 2020 Sep.
2
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people.对无症状人群进行新冠病毒检测的样本合并
Lancet Infect Dis. 2020 Nov;20(11):1231-1232. doi: 10.1016/S1473-3099(20)30362-5. Epub 2020 Apr 28.
3
Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening.多阶段分组检测提高大规模 COVID-19 筛查效率。
基于超图分解的群组检测在新冠病毒中的应用
Nat Commun. 2022 Apr 5;13(1):1837. doi: 10.1038/s41467-022-29389-z.
4
Pooled Testing Strategies for SARS-CoV-2 diagnosis: A comprehensive review.聚合检测策略在 SARS-CoV-2 诊断中的应用:一篇全面的综述。
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115432. doi: 10.1016/j.diagmicrobio.2021.115432. Epub 2021 May 17.
5
Optimizing the diagnostic capacity for COVID-19 PCR testing for low resource and high demand settings: The development of information-dependent pooling protocol.优化低资源高需求环境下 COVID-19 PCR 检测的诊断能力:信息依赖型合并检测方案的制定。
J Glob Health. 2020 Dec;10(2):020515. doi: 10.7189/jogh.10.020515. Epub 2020 Dec 30.
6
Considerations for Group Testing: A Practical Approach for the Clinical Laboratory.分组检测的考量因素:临床实验室的实用方法
Clin Biochem Rev. 2020 Dec;41(3):79-92. doi: 10.33176/AACB-20-00007.
7
COVID-19 Pandemic: Group Testing.新冠疫情:分组检测
Front Med (Lausanne). 2020 Aug 18;7:522. doi: 10.3389/fmed.2020.00522. eCollection 2020.
8
Updates on laboratory investigations in coronavirus disease 2019 (COVID-19).2019年冠状病毒病(COVID-19)实验室检查的最新进展。
Acta Biomed. 2020 Sep 7;91(3):e2020030. doi: 10.23750/abm.v91i3.10187.
J Clin Virol. 2020 Jul;128:104382. doi: 10.1016/j.jcv.2020.104382. Epub 2020 Apr 23.
4
Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools.评价多份样本混合的 COVID-19 RT-qPCR 检测。
Clin Infect Dis. 2020 Nov 19;71(16):2073-2078. doi: 10.1093/cid/ciaa531.
5
Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19.无症状传播,当前控制新冠疫情策略的致命弱点。
N Engl J Med. 2020 May 28;382(22):2158-2160. doi: 10.1056/NEJMe2009758. Epub 2020 Apr 24.
6
CRISPR-Cas12-based detection of SARS-CoV-2.基于 CRISPR-Cas12 的 SARS-CoV-2 检测。
Nat Biotechnol. 2020 Jul;38(7):870-874. doi: 10.1038/s41587-020-0513-4. Epub 2020 Apr 16.
7
COVID-19: extending or relaxing distancing control measures.新型冠状病毒肺炎:延长或放宽社交距离控制措施。
Lancet Public Health. 2020 May;5(5):e236-e237. doi: 10.1016/S2468-2667(20)30072-4. Epub 2020 Mar 25.
8
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.估算 2020 年日本横滨钻石公主号游轮上的 2019 年冠状病毒病(COVID-19)病例的无症状比例。
Euro Surveill. 2020 Mar;25(10). doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
9
Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19).新型冠状病毒感染(COVID-19)无症状感染率的估计。
Int J Infect Dis. 2020 May;94:154-155. doi: 10.1016/j.ijid.2020.03.020. Epub 2020 Mar 14.
10
How will country-based mitigation measures influence the course of the COVID-19 epidemic?基于国家的缓解措施将如何影响新冠疫情的发展进程?
Lancet. 2020 Mar 21;395(10228):931-934. doi: 10.1016/S0140-6736(20)30567-5. Epub 2020 Mar 9.